Over 900 biotech medicines in development in USA, targeting more than 100 diseases

The USA’s biopharmaceutical research companies have 901 biotechnology medicines and vaccines in development to target more than 100 debilitating and life-threatening diseases, such as cancer, arthritis and diabetes, according to a new report by the Pharmaceutical Research and Manufacturers of America (PhRMA).

The medicines in development - all in either clinical trials or under Food and Drug Administration review - include 353 for cancer and related conditions, 187 for infectious diseases, 69 for autoimmune diseases and 59 for cardiovascular diseases.

There are also 44 treatments for neurologic disorders, 40 for respiratory conditions, 39 for HIV infection, 32 for blood disorders, 28 for skin disorders, 27 for digestive conditions, 24 for diabetes and related conditions, 22 for musculoskeletal disorders, 20 for eye conditions, 19 for genetic disorders, 18 for transplantation and five for growth disorders, notes the report , the full text and tables detailing each product of which is available on the trade group’s web site ( www.phrma.org).